<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory YH Lip, MD, FRCPE, FESC, FACC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Russell D Hull, MBBS, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James D Douketis, MD, FRCPC, FACP, FCCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H412636">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Deep vein thrombosis (DVT) and acute pulmonary embolism (PE) are two manifestations of venous thromboembolism. The mainstay of therapy for DVT is anticoagulation, provided there is no contraindication. Thrombolysis is occasionally needed.
        </p>
        <p>
         An overview of the treatment of lower extremity DVT (distal and proximal), including treatment of special populations of patients with DVT, is discussed in this topic. Initial, long-term, and extended (indefinite) anticoagulation for DVT, as well as the treatment of PE and upper extremity DVT, are discussed in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Approach to treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1138350780">
         <span class="h1">
          NOMENCLATURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the purposes of discussion in this topic, the following terms apply  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Provoked DVT
         </strong>
         – A provoked DVT is one that is precipitated by a known event (eg, surgery, hospital admission, estrogen). It is also referred to as DVT associated with an identifiable risk factor(s). Risk factors can be transient or persistent. Examples are in the table  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unprovoked DVT
         </strong>
         – Unprovoked DVT is one that occurs in the absence of identifiable risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proximal DVT
         </strong>
         – Proximal DVT is one that is located in the popliteal, femoral, or iliac veins  (
         <a class="graphic graphic_table graphicRef77469" href="/z/d/graphic/77469.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distal DVT
         </strong>
         – Isolated distal DVT (also known as calf vein DVT) has no proximal component, is located below the knee, and is confined to the calf veins (peroneal, posterior, anterior tibial, and muscular veins). Most calf vein DVTs are located in the posterior tibial and peroneal veins while anterior tibial and muscular vein DVTs are uncommonly involved; the
         <strong>
          popliteal
         </strong>
         vein is not involved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phases of anticoagulation
         </strong>
         – Long-term anticoagulant therapy is typically administered for a finite period of time beyond initiation, usually three to six months and occasionally up to 12 months. Extended anticoagulation refers to therapy that is administered beyond the finite period, sometimes indefinitely. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Direct factor Xa and thrombin inhibitors
         </strong>
         – Direct factor Xa and thrombin inhibitors have been referred to as newer/novel oral anticoagulants, non-vitamin K antagonist oral anticoagulants, direct oral anticoagulants, and target-specific oral anticoagulants [
         <a href="#rid2">
          2,3
         </a>
         ]. Throughout this topic, we refer to these agents by their pharmacologic class, direct factor Xa and thrombin inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The terms provoked and unprovoked may be falling out of favor and use of other terms such as “transient/reversible provoking risk factor”, “persistent provoking risk factor”, and “no identifiable provoking risk factor” may be preferred  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 1
         </a>
         ). Further discussion is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Identify baseline risk based upon presence or absence of risk factors and number of events'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2891829812">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for treatment are presented for proximal and distal DVT.
        </p>
        <p class="headingAnchor" id="H401183128">
         <span class="h2">
          Proximal DVT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with acute proximal DVT (eg, popliteal, femoral, or iliac vein DVT  (
         <a class="graphic graphic_table graphicRef77469" href="/z/d/graphic/77469.html" rel="external">
          table 2
         </a>
         )), we recommend anticoagulation rather than no anticoagulation, provided the risk of bleeding is not high  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131964" href="/z/d/graphic/131964.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Assessing bleeding risk'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         This approach is supported by one older randomized trial that demonstrated a survival benefit compared with no anticoagulation [
         <a href="#rid4">
          4
         </a>
         ], data that support a low rate of venous thromboembolism (VTE) recurrence in patients treated with variable durations of anticoagulant therapy, and the higher risk of embolization from thrombus located in the proximal veins compared with the distal veins [
         <a href="#rid5">
          5,6
         </a>
         ]. Data are strongest for symptomatic patients compared with asymptomatic patients. The recommendation for asymptomatic patients is based upon indirect evidence from patients with symptomatic proximal DVT and the rationale that regardless of symptoms, proximal DVT is likely to have a high risk of embolization. These data are discussed in detail separately. (See
         <a class="local">
          'Anticoagulant therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The greatest benefit of anticoagulation occurs within the first few days or weeks of the initial event. As an example, one meta-analysis of 13 prospective cohort studies and 56 randomized clinical trials reported rates of recurrent VTE and fatal VTE during the first three months of anticoagulant therapy as 3.4 and 0.4 percent, respectively [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         The risk of embolization is higher with proximal than distal DVT. Older studies reported that over 90 percent of acute pulmonary embolism (PE) arise from the proximal veins [
         <a href="#rid5">
          5,6
         </a>
         ]. Another prospective analysis of 1643 patients anticoagulated for acute DVT reported that the mortality rate of proximal DVT is twice that of distal DVT (8 versus 4 percent) [
         <a href="#rid9">
          9
         </a>
         ]; however, most of the excess mortality was cancer-related and not due to PE. Management of distal DVT is discussed below. (See
         <a class="local">
          'Distal DVT'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Distal DVT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of isolated distal DVT varies among centers and clinicians and represents a major challenge therapeutically  (
         <a class="graphic graphic_algorithm graphicRef131963" href="/z/d/graphic/131963.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. We use symptoms as well as other clinical features to help us select patients for therapy. In general, those considered at high risk of embolization should be treated with anticoagulant therapy unless there is a contraindication while those at low risk of embolization may undergo observation with serial ultrasound. What is considered high-risk and low-risk is discussed below. (See
         <a class="local">
          'High risk of embolization: Anticoagulation'
         </a>
         below and
         <a class="local">
          'Low risk of embolization: Surveillance'
         </a>
         below.)
        </p>
        <p>
         This approach is based upon the rationale that patients with isolated distal DVT are at lower risk of embolization (approximately half the risk) than those with proximal DVT and that in some patients, distal DVTs resolve spontaneously without therapy [
         <a href="#rid5">
          5,6,9,11-23
         </a>
         ].
        </p>
        <p>
         When the decision is made to anticoagulate patients with isolated distal DVT, full therapeutic anticoagulation should be administered similar to those with proximal DVT. (See
         <a class="local">
          'Anticoagulant therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H310146110">
         <span class="h3">
          High risk of embolization: Anticoagulation
         </span>
        </p>
        <p class="headingAnchor" id="H3596411124">
         <span class="h4">
          Symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For
         <strong>
          most
         </strong>
         patients with symptomatic isolated distal DVT of the lower extremity, we suggest therapeutic anticoagulation rather than serial compression ultrasonography, provided the risk of bleeding is not high [
         <a href="#rid10">
          10,11,24,25
         </a>
         ]. (See
         <a class="local">
          'Patients at low risk of bleeding'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p>
         However, there are exceptions to this general rule of thumb. Some patients with distal DVT who have minor symptoms and who have features that support a low risk of embolization  (
         <a class="graphic graphic_table graphicRef139729" href="/z/d/graphic/139729.html" rel="external">
          table 4
         </a>
         ) may reasonably opt out of anticoagulation and undergo surveillance. Low-risk features are described below. (See
         <a class="local">
          'Low risk of embolization: Surveillance'
         </a>
         below and
         <a class="local">
          'Patient selection'
         </a>
         below.)
        </p>
        <p>
         Support for this approach is based upon a presumed higher likelihood of embolization (when compared with asymptomatic patients) and the proven efficacy of anticoagulation in reducing clot extension in this population [
         <a href="#rid11">
          11-22,26-28
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Natural history studies suggest that when left untreated, approximately one-third of patients with symptomatic isolated distal DVT will develop extension into the proximal veins, most often within the first two weeks after diagnosis [
         <a href="#rid12">
          12-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several meta-analyses have reported a reduction in the risk of recurrent VTE and lower rates of propagation in patients with distal DVT who were anticoagulated compared with those who did not receive anticoagulant therapy [
         <a href="#rid10">
          10,26,27
         </a>
         ]. In a meta-analysis of 28 studies of patients with isolated DVT, anticoagulant therapy resulted in a 6 percent reduction in VTE recurrence (2.9 versus 9.1 percent; risk reduction [RR] 0.34, 95% CI 0.15-0.77) [
         <a href="#rid10">
          10
         </a>
         ]. The risk of major bleeding was wide (RR 0.76, 95% CI 0.13-4.62; 0.4 versus 0.8 percent). Mortality was unchanged.
        </p>
        <p>
        </p>
        <p>
         In asymptomatic patients with isolated distal DVT, surveillance is appropriate unless risk factors for proximal extension are present  (
         <a class="graphic graphic_table graphicRef139729" href="/z/d/graphic/139729.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Low risk of embolization: Surveillance'
         </a>
         below and
         <a class="local">
          'Evidence of or risk factors for proximal extension'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H320161808">
         <span class="h4">
          Evidence of or risk factors for proximal extension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several factors place patients with distal DVT at risk for embolization and should prompt anticoagulant therapy, regardless of symptoms  (
         <a class="graphic graphic_table graphicRef139729" href="/z/d/graphic/139729.html" rel="external">
          table 4
         </a>
         ). This includes patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombus extension into or close to (eg, within 1 to 2 cm) the proximal popliteal vein
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unprovoked DVT (see
         <a class="local">
          'Nomenclature'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D-dimer 500 ng/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive thrombosis involving multiple veins (eg, &gt;5 cm in length, &gt;7 mm in diameter)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent/irreversible risk factors such as active cancer [
         <a href="#rid29">
          29
         </a>
         ] or prolonged immobility  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior DVT or PE
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inpatient status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronavirus disease 2019 (COVID-19)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient preference
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H505990327">
         <span class="h3">
          Low risk of embolization: Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         For select patients with isolated distal DVT who are considered at low risk of embolization, we suggest surveillance for two weeks with serial lower extremity compressive ultrasound (CUS) to look for extension of thrombus into the proximal veins  (
         <a class="graphic graphic_table graphicRef77469" href="/z/d/graphic/77469.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1736970801">
         <span class="h4">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Suitable candidates for surveillance include patients with any one or more of the following  (
         <a class="graphic graphic_table graphicRef139729" href="/z/d/graphic/139729.html" rel="external">
          table 4
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minor thrombosis in the muscular veins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A negative D-dimer level (&lt;500 ng/mL)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nondiagnostic ultrasonography results
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No symptoms (or minor symptoms)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No risk factors for proximal extension (see
         <a class="local">
          'Evidence of or risk factors for proximal extension'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High risk of or contraindications to bleeding (see
         <a class="local">
          'Patients at high risk of bleeding'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient preference
        </p>
        <p>
        </p>
        <p>
         Patients with isolated distal DVT who are at high risk of bleeding or have a strong preference not to receive anticoagulant therapy should also undergo surveillance off of anticoagulation.
        </p>
        <p>
         Support for this approach is derived from several retrospective and prospective observational studies, which have reported that limited thrombosis confined to the muscular veins has a low risk of extension without therapy compared with extensive thrombosis of multiple calf veins (approximately 3 versus 15 percent) [
         <a href="#rid11">
          11-14,16,19,20,25
         </a>
         ]. In addition, natural history studies suggest that if extension does not occur within two weeks of diagnosis, it is unlikely to occur [
         <a href="#rid12">
          12-21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1039407478">
         <span class="h4">
          Surveillance ultrasound protocol
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal frequency, duration, and method of surveillance are unknown. We generally survey patients for thrombus extension or resolution with proximal CUS once a week for two weeks, or earlier if patients develop worsening or new symptoms [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         For surveillance, we prefer proximal rather than whole leg CUS because it is sufficient for the detection of proximal DVT, where the indication for anticoagulation is strong. (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'Diagnostic ultrasonography suspected first DVT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2303658429">
         <span class="h4">
          Surveillance follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon the results of CUS, the following is appropriate:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If thrombus resolves, no anticoagulation is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If thrombus extension
         <strong>
          into
         </strong>
         the proximal veins is observed, patients should be anticoagulated or treated with an inferior vena cava filter when a contraindication to anticoagulation exists. (See
         <a class="local">
          'Patients at low risk of bleeding'
         </a>
         below and
         <a class="local">
          'Patients at high risk of bleeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If thrombus extends
         <strong>
          toward
         </strong>
         the proximal veins (eg, within 1 to 2 cm) but remains confined to the calf, we suggest anticoagulation rather than continued surveillance with CUS. (See
         <a class="local">
          'Patients at low risk of bleeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in whom clot does not resolve but remains
         <strong>
          stable
         </strong>
         , longer periods of surveillance may be required.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H102101510">
         <span class="h1">
          ASSESSING BLEEDING RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with DVT in whom anticoagulation is newly indicated, the decision to anticoagulate should be individualized and the benefits of embolization prevention carefully weighed against the risk of bleeding  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef107543" href="/z/d/graphic/107543.html" rel="external">
          table 5
         </a>
         ). Most clinicians agree with the following [
         <a href="#rid11">
          11,30,31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low risk – Patients with a three-month bleeding risk less than 2 percent (low risk) should be anticoagulated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High risk – Patients with a bleeding risk more than 13 percent (high risk) should not be anticoagulated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate risk – For patients with a bleeding risk between these values (moderate risk), there is no agreement regarding the preferred approach such that the decision to anticoagulate in this population must be individualized according to the values and preferences of the patient as well as the risk-benefit ratio, which may change over time.
        </p>
        <p>
        </p>
        <p>
         Tools are available for estimating the risk of bleeding in anticoagulated individuals. However, no one index can reliably predict bleeding risk in a particular patient such that for practical purposes, many clinicians use a gestalt estimate to assess the bleeding risk. A venous thromboembolism (VTE) specific bleeding score has been generated (VTE-Bleed) using data derived from randomized trials that studied the direct oral thrombin inhibitor,
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         , as an anticoagulant for VTE [
         <a href="#rid30">
          30
         </a>
         ]; however, VTE-Bleed requires external validation before it can be recommended for bleeding assessment in patients undergoing initial anticoagulation. Details regarding the use of scoring systems that estimate the risk of bleeding and bleeding risk assessment for those in whom indefinite anticoagulation is being considered are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants", section on 'Bleeding risk scores'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Assessing the risk of bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4118924795">
         <span class="h1">
          PATIENTS AT LOW RISK OF BLEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with DVT of the lower extremity who are at low bleeding risk, anticoagulation is the mainstay of therapy, provided there are no contraindications. The primary objective of anticoagulation is the prevention of further propagation and complications of DVT such as acute pulmonary embolism (PE), recurrent DVT, post-thrombotic (postphlebitic) syndrome, and death.
        </p>
        <p>
         We treat patients who have a definitive diagnosis of DVT, usually made on compressive ultrasound (CUS) of the lower extremities. When DVT is found incidentally (usually computed tomography [CT]), the diagnosis should be sought using CUS before anticoagulation due to the poorer sensitivity and specificity of CT. The diagnosis of DVT and empiric anticoagulation strategies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'Diagnostic ultrasonography suspected first DVT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Empiric anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2499297092">
         <span class="h2">
          Anticoagulant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients, anticoagulant therapy should be started immediately as a delay in therapy may increase the risk of potentially life-threatening embolization [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agent selection
         </strong>
         – Several factors influence agent choice and are listed in the table  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 6
         </a>
         ). Selecting an anticoagulant, dosing for parenteral and oral anticoagulants, and empiric anticoagulation are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Selection of agent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – In general, we treat for a minimum of three months. Further discussion on duration of therapy and indications for indefinite anticoagulation are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Duration of treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H726449277">
         <span class="h2">
          Outpatient versus inpatient therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several randomized trials and meta-analyses suggest that, in select patients, treatment at home is safe and effective [
         <a href="#rid11">
          11,34-48
         </a>
         ]. The decision to treat DVT in the outpatient setting should be made in the context of the patient's understanding of the risk-benefit ratio, preferences, and clinical condition. Importantly, anticoagulant therapy should
         <strong>
          not
         </strong>
         be delayed while the decision is being made whether to treat the patient at home.
        </p>
        <p class="headingAnchor" id="H2295241851">
         <span class="h3">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         When considering outpatient administration of low molecular weight (LMW) heparin, patient selection is critical:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outpatient therapy can be considered when patients have
         <strong>
          all
         </strong>
         of the following features  (
         <a class="graphic graphic_table graphicRef70140" href="/z/d/graphic/70140.html" rel="external">
          table 7
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemodynamic stability
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A low risk of bleeding
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No severe renal insufficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A practical system in place at home for the administration and surveillance of anticoagulant therapy (eg, good living conditions, caregiver support, phone access, understanding and ability to return to the hospital should deterioration occur)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outpatient therapy is
         <strong>
          not
         </strong>
         appropriate in patients with any one of the following [
         <a href="#rid49">
          49
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Massive DVT (eg, iliofemoral DVT, phlegmasia cerulea dolens)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Concurrent symptomatic PE
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High risk of bleeding on anticoagulant therapy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Comorbid conditions or other factors that warrant in-hospital care
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2357920091">
         <span class="h3">
          Agent selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selecting an agent for outpatient therapy should be individualized and is dependent upon the risk of bleeding, patient comorbidities, preferences, cost, and convenience. For most patients in whom outpatient therapy is selected, we suggest anticoagulation with either
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         or
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         (monotherapy; ie, no need for heparin pretreatment). As alternative regimens, LMW heparin overlapped with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (dual therapy) or pretreatment with LMW heparin followed by the administration of either
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         or
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         (dual therapy) are both appropriate.
        </p>
        <p>
         Data that support these regimens are discussed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rivaroxaban
         </strong>
         <strong>
          or
         </strong>
         <strong>
          apixaban
         </strong>
         <strong>
          monotherapy
         </strong>
         – Randomized trials of
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         reported efficacy of both of these factor Xa inhibitors as the sole initial anticoagulant (monotherapy; ie, without heparin pretreatment) [
         <a href="#rid50">
          50,51
         </a>
         ]. Although short periods (&lt;48 hours) of heparin were allowed prior to randomization and studies were not specifically performed in the outpatient population, our experience with these agents is that they are safe and effective when administered to the outpatient population. These studies and dosing are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin plus
         </strong>
         <strong>
          warfarin
         </strong>
         – Evidence to support this combination is derived from randomized trials and meta-analyses that have compared LMW heparin delivered at home following immediate discharge from the emergency or outpatient department or following a brief inpatient stay (eg, one day) [
         <a href="#rid11">
          11,41,45
         </a>
         ]. However, these trials have been intrinsically flawed because of differences in the LMW heparin used, the follow-up therapy used (
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and LMW heparin), and randomization strategies. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Low molecular weight heparin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, one meta-analysis of six randomized trials totaling 1708 patients with acute DVT compared outpatient use of LMW heparin with inpatient IV
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) [
         <a href="#rid11">
          11
         </a>
         ]. Outpatient therapy with LMW heparin was associated with reductions in the rate of recurrent venous thromboembolism (risk reduction [RR] 0.61, 95% CI 0.42-0.9), major bleeding (RR 0.67, 95% CI 0.33-1.36), and mortality (RR 0.72, 95% CI 0.45-1.15) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dosing of LMW heparin for outpatients is similar to inpatients. However, for
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         we prefer to use the 1 mg/kg twice daily dosing regimen rather than the 1.5 mg/kg once daily regimen since the twice daily regimen has been better validated. Dosing regimens are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation", section on 'Dosing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin followed by
         </strong>
         <strong>
          dabigatran
         </strong>
         <strong>
          or
         </strong>
         <strong>
          edoxaban
         </strong>
         – Randomized trials that support efficacy of this combination only studied efficacy for
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         (direct thrombin inhibitor) and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         (factor Xa inhibitor) when patients were treated with these agents following a 5- to 10-day course of a parenteral anticoagulant (usually LMW heparin; ie, dual therapy). Consequently, we suggest that dabigatran and edoxaban
         <strong>
          not
         </strong>
         be routinely used as a monotherapy for initial anticoagulation in outpatients but can be used in this setting provided that an initial course of parenteral anticoagulant has been administered [
         <a href="#rid52">
          52,53
         </a>
         ]. These studies, dosing, and how to transition from heparin to these agents are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Subcutaneous UFH has not been adequately studied in this population and as such cannot be routinely recommended. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
         Cost savings due to the avoidance of an inpatient stay is a frequently cited advantage of outpatient anticoagulation, and are estimated to range from $500 to $2500 per patient [
         <a href="#rid41">
          41,54-63
         </a>
         ]. However, these studies have compared LMW heparin with UFH and were limited in their sensitivity analysis.
        </p>
        <p>
         The outpatient treatment of PE is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H256309218">
         <span class="h1">
          PATIENTS AT HIGH RISK OF BLEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with contraindications or who have a high risk of bleeding with anticoagulation, the following is appropriate:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with acute proximal DVT of the lower extremity, we recommend prompt placement of an inferior vena cava (IVC) filter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with acute distal DVT may be managed with surveillance ultrasonography rather than IVC filter placement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details of IVC filter placement are discussed separately. (See
         <a class="local">
          'Inferior vena cava filter'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H354538131">
         <span class="h2">
          Contraindications to anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Absolute contraindications to anticoagulation include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe bleeding diathesis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent, planned, or emergency high bleeding-risk surgery/procedure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major trauma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute intracranial hemorrhage
        </p>
        <p>
        </p>
        <p>
         Relative contraindications to anticoagulation include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent bleeding from multiple gastrointestinal telangiectasias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracranial or spinal tumors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large abdominal aortic aneurysm with concurrent severe hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stable aortic dissection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent, planned, or emergent low bleeding-risk surgery/procedure
        </p>
        <p>
        </p>
        <p>
         Thrombocytopenia is not always a contraindication to anticoagulation (eg, those with counts &gt;50,000/microL). Recommendations for specific patient groups and platelet counts are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117208.html" rel="external">
          "Anticoagulation in individuals with thrombocytopenia"
         </a>
         .)
        </p>
        <p>
         Patients with a
         <strong>
          history
         </strong>
         of intracranial hemorrhage (eg, due to aneurysm successfully ablated) may be candidates for anticoagulation, but the decision should be individualized and depends upon the risk of embolic events weighed against the risk of recurrent bleeding. Further details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Resumption of anticoagulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129071.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis", section on 'Anticoagulation'
         </a>
         .)
        </p>
        <p>
         Special consideration should also be given to avoiding anticoagulation, when feasible, in older patients (eg, &gt;65 years) with a history of multiple falls and the presence of more than one factor that elevates the bleeding risk. Such patients are at high risk of bleeding or have a high risk of a catastrophic result should a bleed occur. Consequently, the decision to anticoagulate in these populations should be even more cautious to allow the benefits of VTE prevention to be carefully weighed against the risk of bleeding.
        </p>
        <p>
         Patients with a recent episode of epistaxis or heavy menstrual bleeding are not generally considered high risk for bleeding and anticoagulation can usually be administered safely in this population.
        </p>
        <p>
         The management of anticoagulation perioperatively and assessing the risk of bleeding are discussed separately. (See
         <a class="local">
          'Assessing bleeding risk'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3517714291">
         <span class="h2">
          Inferior vena cava filter
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major purpose of IVC filters is the prevention of thrombus embolization to the lung.
        </p>
        <p class="headingAnchor" id="H936335950">
         <span class="h3">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following is our approach to IVC filter placement:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with acute DVT, we do
         <strong>
          not
         </strong>
         routinely insert IVC filters, as stand-alone or adjunctive therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We typically use IVC filters in patients with acute proximal DVT who have a contraindication to anticoagulant therapy (eg, recent surgery, hemorrhagic stroke, active bleeding) [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="local">
          'Patients at high risk of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We also consider placement of an IVC filter as an adjunct in patients with recurrent embolism despite adequate anticoagulation, particularly patients in whom an additional embolic event would be poorly tolerated (eg, those with poor cardiopulmonary reserve from massive pulmonary embolism [PE] or underlying cardiopulmonary disease, hemodynamically unstable patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The efficacy of IVC filter placement in patients with symptomatic isolated distal DVT is unknown and not generally performed unless the thrombus shows signs of progression during surveillance. (See
         <a class="local">
          'Low risk of embolization: Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in whom an IVC filter is placed and the risk of bleeding is subsequently assessed as low, we typically administer a conventional course of anticoagulation therapy and remove the filter when feasible [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Several practical factors that may influence the decision to place an IVC filter should be considered in every patient:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The site of origin of the embolic event must be such that the filter will provide a beneficial effect. For example, most IVC filters are placed in the infrarenal portion of the IVC. This position will prevent embolization of lower extremity thrombus to the lung but will not be of prophylactic value for thrombus located in the renal veins, a cardiac chamber, or the upper extremity veins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IVC filter placement is associated with its own set of complications (eg, guidewire entrapment, local hemorrhage, fracture, embolization) and mortality (0.12 to 0.3 percent) such that weighing these risks against those of recurrence is prudent. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications", section on 'Mortality'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with PE who do not have proven thrombus in the lower extremities and who have a contraindication to anticoagulation, we typically place an IVC filter. This is because thrombus can quickly reform in the leg veins after embolization and may also remain undetected in the pelvis or calf veins with the potential to embolize. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Inferior vena cava filters'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Many types of IVC filters are available, but none is superior to another  (
         <a class="graphic graphic_table graphicRef51423" href="/z/d/graphic/51423.html" rel="external">
          table 8
         </a>
         ). In general, we prefer retrievable IVC filters but retrieval rates are variable [
         <a href="#rid65">
          65-68
         </a>
         ]. Alongside an overall decline in rates of IVC filter placement, there has been a rise in IVC filter retrieval rates [
         <a href="#rid69">
          69
         </a>
         ]. Early consideration of filter retrieval, coupled with communication with the inserting proceduralist, can facilitate IVC filter retrieval.
        </p>
        <p>
         The placement and complications of IVC filters are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1294709919">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retrospective and observational case series report that rates of recurrent PE following IVC filter insertion are low (2 to 4 percent in most series) [
         <a href="#rid64">
          64,70-72
         </a>
         ]. While some cohort studies report lower short-term fatality rates in patients in whom an IVC filter is placed, there is no robust evidence that IVC filters prevent PE-related death [
         <a href="#rid64">
          64,73,74
         </a>
         ].
        </p>
        <p>
         IVC filters may prevent PE in the short-term but at the expense of an increased rate of DVT. IVC filter insertion has also been associated with thrombosis at the filter insertion site, particularly in those in whom anticoagulation is contraindicated and those with known DVT [
         <a href="#rid70">
          70,75-78
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one of the largest trials to date (PREPIC1) that examined the effectiveness of IVC filters, 400 patients with
         <strong>
          proximal DVT
         </strong>
         were randomly assigned to either standard anticoagulation alone or anticoagulation plus insertion of an IVC filter [
         <a href="#rid79">
          79
         </a>
         ]. During the first 12 days after randomization, significantly fewer patients in the IVC filter group developed a PE (1 versus 5 percent). However, after a two-year follow-up period, there were no significant differences in survival or symptomatic PE between the two groups, and a significantly higher rate of DVT was observed among patients who had received an IVC filter (21 versus 12 percent). An eight-year follow-up of the same population of patients confirmed these findings that filter placement was associated with a successful reduction in the rate of PE (15 versus 6 percent) but an increase in the rate of DVT (35 versus 28 percent) [
         <a href="#rid80">
          80
         </a>
         ]. No difference in mortality was reported. Whether the increased rates of DVT were reflective of older nonretrievable filters is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of IVC filters in patients with PE who have contraindications to anticoagulation are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Inferior vena cava filter'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A review of retrospective case series reported that venous thrombosis at the site of insertion occurred in 10 percent of patients who had an IVC filter placed for a contraindication to anticoagulation [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective observational study of patients in whom permanent filters were placed reported that filter thrombosis occurred in 30 percent, DVT in 20 percent, and PE in 5 percent [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The risk of post-thrombotic syndrome (PTS) may also be increased in patients who receive an IVC filter. Two systematic reviews in patients in whom a permanent filter was placed for primary or secondary prevention reported high rates of the signs and symptoms of PTS (50 and 20 percent, respectively) [
         <a href="#rid76">
          76,77
         </a>
         ].
        </p>
        <p>
         Whether the use of retrievable filters reduce the risk of filter-associated DVT is unknown.
        </p>
        <p class="headingAnchor" id="H733049823">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Special populations of patients with acute DVT require specific consideration  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 6
         </a>
         ) and are mostly discussed in the linked sections below.
        </p>
        <p class="headingAnchor" id="H34074030">
         <span class="h2">
          Patients with malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H146406374">
         <span class="h2">
          Antiphospholipid syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">
          "Management of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H256309230">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">
          "Use of anticoagulants during pregnancy and postpartum"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4016861759">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5918.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1641546959">
         <span class="h2">
          May-Thurner syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110055.html" rel="external">
          "May-Thurner syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15184017">
         <span class="h2">
          Phlegmasia cerulea dolens
         </span>
         <span class="headingEndMark">
          —
         </span>
         (See
         <a class="local">
          'Thrombolytic therapy and thrombectomy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139136.html" rel="external">
          "Phlegmasia and venous gangrene"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2904396816">
         <span class="h2">
          Heparin-induced thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a DVT and a diagnosis of heparin-induced thrombocytopenia (HIT), all forms of heparin should be discontinued. This includes
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         , low molecular weight heparin, heparin flushes, heparin-bonded catheters, and heparin-containing medications. Immediate anticoagulation with a nonheparin anticoagulant (eg,
         <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">
          argatroban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9320" href="/z/d/drug information/9320.html" rel="external">
          danaparoid
         </a>
         ,
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         ) is indicated, unless there is a strong contraindication to anticoagulation. The diagnosis and management of patients with HIT are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H408123141">
         <span class="h2">
          Inherited thrombophilias
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many cases, the presence of an inherited thrombophilia does not appreciably alter treatment decisions, such as choice of an anticoagulant or duration of anticoagulation, but there may be specific circumstances in which the thrombophilia does affect management (eg, need for antithrombin [AT] administration in some individuals with AT deficiency). Details are presented in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factor V Leiden – (See
         <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">
          "Factor V Leiden and activated protein C resistance", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prothrombin G20210A mutation – (See
         <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">
          "Prothrombin G20210A", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein S deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">
          "Protein S deficiency", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein C deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency", section on 'Thromboembolism management'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antithrombin deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">
          "Antithrombin deficiency", section on 'VTE treatment (hereditary deficiency)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H256309236">
         <span class="h1">
          SUPPORTIVE THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional considerations for patients diagnosed with acute DVT of the lower extremity include ambulation and graduated compression stockings (GCS) for the prevention of post-thrombotic (postphlebitic) syndrome (PTS).
        </p>
        <p class="headingAnchor" id="H256309242">
         <span class="h2">
          Ambulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with acute DVT, we encourage early ambulation as soon as is feasible, provided the patient is therapeutically anticoagulated. From a practical standpoint, patients with severe DVT or phlegmasia cerulea dolens may be confined to bed for the first 24 hours since ambulation may be difficult or painful.
        </p>
        <p>
         This approach is supported by several small randomized studies and meta-analyses that have shown that early ambulation does not increase the risk of recurrent or fatal pulmonary embolism (PE) [
         <a href="#rid34">
          34,35,81-89
         </a>
         ].
        </p>
        <p>
         The risk of PE during more aggressive forms of exercise, physical therapy, or rehabilitation is unknown. However, in this setting we typically gradually increase exercise training as tolerated by the patient.
        </p>
        <p>
         When symptoms such as pain or leg edema limit ambulation, GCS may be useful for symptomatic relief to facilitate ambulation.
        </p>
        <p class="headingAnchor" id="H256309248">
         <span class="h2">
          Graduated compression stockings
         </span>
         <span class="headingEndMark">
          —
         </span>
         While elastic GCS that provide 30 to 40 mmHg of ankle pressure have traditionally been used to prevent PTS, we do not
         <strong>
          routinely
         </strong>
         use elastic GCS for this purpose. This preference is based upon randomized studies that have not shown clear consistent benefit from GCS in this setting. However, if the decision is made to use GCS, they should be started after anticoagulant therapy, within two weeks of the diagnosis, and continued for two years.
        </p>
        <p>
         Evidence evaluating elastic GCS for the prevention of PTS is conflicting, with smaller trials suggesting benefit and one large randomized trial reporting no benefit [
         <a href="#rid11">
          11,61,90-101
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While a meta-analysis of five randomized trials reported marginal benefit with elastic GCS (risk ratio 0.62, 95% CI 0.38-1.01), the quality of evidence was low and the benefit is questionable [
         <a href="#rid101">
          101
         </a>
         ]. Most trials were hampered by methodologic flaws, including imprecision, heterogeneity (eg, differing criteria for the assessment of PTS [Ginsberg or Villalta criteria]), risk of bias (lack of blinding, variable initial randomization periods and control groups [eg, no stockings, stockings with 5 mmHg pressure at the ankles, GCS one to two sizes too big]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, the one well-conducted randomized placebo-controlled trial of 806 patients with first proximal DVT reported no difference in the rate of PTS with GCS as measured by the less stringent Ginsberg criteria (leg pain and swelling one month or more; 14 versus 13 percent) [
         <a href="#rid98">
          98
         </a>
         ]. A similar lack of benefit was reported when the more rigorous Villalta criteria were applied. Based upon this study, we and other experts do not routinely apply GCS for the prevention of PTS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older and smaller randomized trials of patients with acute DVT (first or recurrent) that used the Villalta criteria for PTS suggested that GCS that apply an ankle pressure of 30 to 40 mmHg started within two weeks and continued for two years reduced the occurrence of PTS by 50 percent without increasing the frequency of recurrent venous thromboembolism [
         <a href="#rid91">
          91,92
         </a>
         ]. Patients most likely to benefit included patients with a proximal DVT or prior DVT and those with symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although GCS are not harmful, many patients also decline their use because they are uncomfortable, costly, inconvenient, and often require a healthcare giver for their application. However, a subset of patients with recurrent DVT or moderate to severe symptoms may consider the potential benefits of GCS to outweigh these inconveniences. In such patients, the purpose of GCS is often focused on symptom reduction rather than PTS prevention.
        </p>
        <p>
        </p>
        <p>
         When the decision is made to wear GCS, they should be started
         <strong>
          after
         </strong>
         anticoagulant therapy. This is to avoid the theoretical risk of provoking embolism to the lung from fresh thrombus in the lower extremity. GCS should be continued for two years, replaced every six months, and may require refitting once local swelling is reduced. Alternative approaches of compressive bandages or application of GCS for limited periods (eg, for the duration of anticoagulation) or following thrombolytic therapy have not been adequately evaluated.
        </p>
        <p>
         Contraindications to GCS include skin ulceration, severe arterial insufficiency, allergy to the stocking material, and inability to apply stockings.
        </p>
        <p>
         The use of compression stockings as a
         <strong>
          therapy
         </strong>
         for PTS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8200.html" rel="external">
          "Post-thrombotic (postphlebitic) syndrome", section on 'Compression therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H256309254">
         <span class="h1">
          THROMBOLYTIC THERAPY AND THROMBECTOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with acute lower extremity DVT, anticoagulant therapy alone is sufficient. Routine use of thrombolytic therapy (systemic and catheter-directed) and/or thrombectomy (surgical or catheter-directed) is not indicated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombolysis (usually catheter-directed) is usually reserved for patients with phlegmasia cerulea dolens or massive iliofemoral DVT or for patients who fail therapeutic anticoagulation. Further details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Embolectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombectomy (can be performed via a catheter [eg, suction thrombectomy] or by open surgery) may be the only option in patients who are not suitable candidates for or fail thrombolysis. (See
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration", section on 'Patients at high risk of bleeding or contraindications to thrombolysis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration", section on 'Patients who fail thrombolysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Choosing among these options is often at the discretion of the clinician and dependent upon local expertise and clinical factors, such as contraindications and comorbidities.
        </p>
        <p class="headingAnchor" id="H726448897">
         <span class="h1">
          MONITORING AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         We monitor patients for the complications of both DVT and anticoagulation.
        </p>
        <p>
         Complications of DVT include further thrombus extension, recurrence, embolization, and post-thrombotic (postphlebitic) syndrome. To this end, we monitor clinically for symptoms. We do not routinely follow-up with lower extremity compression ultrasound following anticoagulant therapy unless the patient has symptoms or signs of recurrent or persistent DVT, although this practice varies among clinicians. Details regarding clinical suspicion for recurrence, pulmonary embolism, and the implications of detecting residual vein obstruction after therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'Suspected recurrent DVT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Less well-validated risk factors'
         </a>
         .)
        </p>
        <p>
         We also monitor for anticoagulation-related adverse effects (eg, bleeding, thrombocytopenia) and for the development of conditions that affect the half-life of or contraindications for the anticoagulant used (eg, renal failure, pregnancy, weight gain/loss). Further details regarding monitoring patients on anticoagulant therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Laboratory monitoring/measurement (LMW heparins)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Anticoagulant monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1252700594">
         <span class="h1">
          EVALUATING FOR AN UNDERLYING CAUSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluating patients with DVT for an underlying inheritable or acquired risk factor is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1508630651">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">
          "Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H41">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15362.html" rel="external">
          "Patient education: Deep vein thrombosis (blood clot in the leg) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/693.html" rel="external">
          "Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">
          "Patient education: Warfarin (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H42">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Proximal deep vein thrombosis (DVT) is one that is located in the popliteal, femoral, or iliac veins  (
         <a class="graphic graphic_table graphicRef77469" href="/z/d/graphic/77469.html" rel="external">
          table 2
         </a>
         ). Distal DVT is confined to the calf veins (peroneal, posterior, anterior tibial, and muscular veins)  (
         <a class="graphic graphic_table graphicRef131266" href="/z/d/graphic/131266.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Nomenclature'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection for anticoagulation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Proximal DVT
         </strong>
         – The following is our strategy for anticoagulation in patients with proximal DVT  (
         <a class="graphic graphic_algorithm graphicRef131964" href="/z/d/graphic/131964.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Low risk of bleeding
         </strong>
         – For most patients with acute proximal DVT of the lower extremity in whom the risk of bleeding is
         <strong>
          not high
         </strong>
         (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ), we recommend therapeutic anticoagulation rather than no anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         )  (
         <a class="graphic graphic_algorithm graphicRef131964" href="/z/d/graphic/131964.html" rel="external">
          algorithm 1
         </a>
         ). This approach is supported by older data that demonstrated a survival benefit compared with no anticoagulation. In addition, subsequent data support a low rate of venous thromboembolism recurrence in patients treated with variable durations of anticoagulant therapy and the higher risk of embolization from thrombus located in the proximal veins compared with the distal veins. While data are strongest in symptomatic patients, it is reasonable to expect that the same benefit applies to asymptomatic patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          High risk of bleeding
         </strong>
         – For patients with acute proximal DVT of the lower extremity who have contraindications or a
         <strong>
          high risk
         </strong>
         of bleeding, we suggest prompt placement of an inferior vena cava (IVC) filter (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This approach is based upon data that suggest low rates of pulmonary embolism (PE) when IVC filters are placed. We prefer retrievable filters for the avoidance of long-term complications of filter placement, particularly recurrent DVT. A conventional course of anticoagulation should be administered once the contraindication resolves. (See
         <a class="local">
          'Patients at high risk of bleeding'
         </a>
         above and
         <a class="local">
          'Inferior vena cava filter'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Distal DVT
         </strong>
         – The following is our approach to patients with distal DVT of the lower extremity  (
         <a class="graphic graphic_algorithm graphicRef131963" href="/z/d/graphic/131963.html" rel="external">
          algorithm 2
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Low risk of bleeding, high risk of embolization
         </strong>
         – For patients with distal DVT who are considered to be at high risk of embolization and in whom the risk of bleeding is
         <strong>
          not high
         </strong>
         (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ), we suggest anticoagulation rather than serial monitoring with compression ultrasonography (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This includes most patients who are symptomatic and/or those with features that suggest a high risk of embolization listed on the table  (
         <a class="graphic graphic_table graphicRef139729" href="/z/d/graphic/139729.html" rel="external">
          table 4
         </a>
         ). Support for this approach is based upon a high likelihood of embolization and the proven efficacy of anticoagulation in reducing thrombus extension and subsequent embolization in this population. Occasionally, some patients with minor symptoms who have features that support a low risk of embolization may reasonably opt out of anticoagulation and undergo surveillance. (See
         <a class="local">
          'High risk of embolization: Anticoagulation'
         </a>
         above and
         <a class="local">
          'Symptomatic patients'
         </a>
         above and
         <a class="local">
          'Evidence of or risk factors for proximal extension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Low risk of bleeding and embolization
         </strong>
         – For most patients with distal DVT who are at low risk of embolization and in whom the risk of bleeding is
         <strong>
          not high
         </strong>
         (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 3
         </a>
         ), we suggest surveillance with serial ultrasound over a two-week period rather than anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Features that are considered to be associated with a low risk of embolization are listed in the table  (
         <a class="graphic graphic_table graphicRef139729" href="/z/d/graphic/139729.html" rel="external">
          table 4
         </a>
         ). For patients who exhibit any signs of thrombus extension during surveillance, we suggest anticoagulation rather than continued surveillance (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This approach is derived from data that suggest a low likelihood of proximal extension (and therefore embolization) without therapy in this population. (See
         <a class="local">
          'Low risk of embolization: Surveillance'
         </a>
         above and
         <a class="local">
          'Patient selection'
         </a>
         above and
         <a class="local">
          'Surveillance ultrasound protocol'
         </a>
         above and
         <a class="local">
          'Surveillance follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          High risk of bleeding
         </strong>
         – For patients with acute distal DVT of the lower extremity who have contraindications or a
         <strong>
          high risk
         </strong>
         of bleeding, we suggest surveillance ultrasonography rather than IVC filter placement. If a proximal DVT develops, an IVC filter should be placed. (See
         <a class="local">
          'Patients at high risk of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticoagulation therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial anticoagulation
         </strong>
         – In most patients, anticoagulation should be started immediately as a delay in therapy increases the risk of potentially life-threatening embolization. Selecting an anticoagulant  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 6
         </a>
         ), dosing for parenteral and oral anticoagulants, and empiric anticoagulation are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Selection of agent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatient anticoagulation
         </strong>
         – Outpatient anticoagulation rather than inpatient therapy can be considered when patients are hemodynamically stable, have a low risk of bleeding, do not have severe renal insufficiency, and have a practical system in place at home for the administration and surveillance of anticoagulant therapy  (
         <a class="graphic graphic_table graphicRef70140" href="/z/d/graphic/70140.html" rel="external">
          table 7
         </a>
         ). It is not appropriate in patients with massive DVT (eg, iliofemoral DVT, phlegmasia cerulea dolens), concurrent PE, a high risk of bleeding on anticoagulant therapy, comorbid conditions, or other factors that warrant in-hospital care. (See
         <a class="local">
          'Outpatient versus inpatient therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Long-term anticoagulation
         </strong>
         – In general, we treat for a minimum of three months. Further discussion on duration of therapy and indications for indefinite anticoagulation are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Duration of treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special populations
         </strong>
         – Special populations of patients with acute DVT that require specific consideration are discussed in the linked topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Malignancy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiphospholipid syndrome
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">
          "Management of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnancy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          May-Thurner syndrome
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/110055.html" rel="external">
          "May-Thurner syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Phlegmasia cerulea dolens
         </strong>
         – (See
         <a class="local">
          'Thrombolytic therapy and thrombectomy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Heparin-induced thrombocytopenia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Inherited thrombophilias
         </strong>
         – Details are presented in separate topic reviews:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Factor V Leiden – (See
         <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">
          "Factor V Leiden and activated protein C resistance", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Prothrombin G20210A mutation – (See
         <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">
          "Prothrombin G20210A", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Protein S deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">
          "Protein S deficiency", section on 'Patients with VTE'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Protein C deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency", section on 'Thromboembolism management'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Antithrombin deficiency – (See
         <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">
          "Antithrombin deficiency", section on 'VTE treatment (hereditary deficiency)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ambulation and graduated compression stockings
         </strong>
         – For most patients with acute DVT of the lower extremity who are fully anticoagulated, hemodynamically stable, and whose symptoms are under control (eg, pain, swelling), we encourage early ambulation in preference to bed rest. We suggest that elastic graduated compression stockings (GCS)
         <strong>
          not
         </strong>
         be administered in patients for the prevention of post-thrombotic (postphlebitic) syndrome (PTS) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The latter is based upon data from a randomized trial that suggested no benefit from GCS and the observation that many patients decline their use because they are uncomfortable, costly, inconvenient, and often require a healthcare giver for their application. GCS may be applied for symptom control or established PTS, the details of which are discussed separately. (See
         <a class="local">
          'Ambulation'
         </a>
         above and
         <a class="local">
          'Graduated compression stockings'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8200.html" rel="external">
          "Post-thrombotic (postphlebitic) syndrome", section on 'Compression therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombolytic therapy and thrombectomy
         </strong>
         – For most patients with acute lower extremity DVT, thrombolytic therapy and/or thrombectomy is not indicated. These therapies are usually reserved for patients with phlegmasia cerulea dolens or massive iliofemoral DVT or for patients who fail therapeutic anticoagulation. Thrombolytic therapy is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/121197.html" rel="external">
          "Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes GD, Ageno W, Ansell J, et al. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BARRITT DW, JORDAN SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browse NL, Thomas ML. Source of non-lethal pulmonary emboli. Lancet 1974; 1:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havig O. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand Suppl 1977; 478:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillis C, Crowther MA. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2015; 113:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galanaud JP, Sevestre-Pietri MA, Bosson JL, et al. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 2009; 102:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107:I22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masuda EM, Kistner RL. The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation. Dis Mon 2010; 56:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Righini M, Paris S, Le Gal G, et al. Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 2006; 95:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz T, Schmidt B, Beyer J, Schellong SM. Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis 2001; 12:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdonald PS, Kahn SR, Miller N, Obrand D. Short-term natural history of isolated gastrocnemius and soleal vein thrombosis. J Vasc Surg 2003; 37:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillet JL, Perrin MR, Allaert FA. Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. J Vasc Surg 2007; 46:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lautz TB, Abbas F, Walsh SJ, et al. Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation? Ann Surg 2010; 251:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz T, Buschmann L, Beyer J, et al. Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg 2010; 52:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sales CM, Haq F, Bustami R, Sun F. Management of isolated soleal and gastrocnemius vein thrombosis. J Vasc Surg 2010; 52:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palareti G, Cosmi B, Lessiani G, et al. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost 2010; 104:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Martino RR, Wallaert JB, Rossi AP, et al. A meta-analysis of anticoagulation for calf deep venous thrombosis. J Vasc Surg 2012; 56:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brateanu A, Patel K, Chagin K, et al. Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis. Thromb Haemost 2016; 115:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014; 124:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horner D, Hogg K, Body R, et al. The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial. Chest 2014; 146:1468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franco L, Giustozzi M, Agnelli G, Becattini C. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost 2017; 15:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkilesis G, Kakkos SK, Bicknell C, et al. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev 2020; 4:CD013422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuczmik W, Wysokinski WE, Macedo T, et al. Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies. Mayo Clin Proc 2021; 96:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahajan A, Brunson A, Eldredge J, et al. Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers. Thromb Haemost 2022; 122:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badescu MC, Ciocoiu M, Badulescu OV, et al. Prediction of bleeding events using the VTE-BLEED risk score in patients with venous thromboembolism receiving anticoagulant therapy (Review). Exp Ther Med 2021; 22:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Exter PL, van Es J, Erkens PM, et al. Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism. Am J Respir Crit Care Med 2013; 187:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010; 137:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boccalon H, Elias A, Chalé JJ, et al. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med 2000; 160:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM 2000; 93:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grau E, Tenias JM, Real E, et al. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 2001; 67:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn A, Bioh D, Beran M, et al. Effect of intravenous heparin administration on duration of hospitalization. Mayo Clin Proc 2004; 79:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn AS, Schechter C, Gotlin A, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001; 110:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal JB, Bolger DT, Jenckes MW, et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med 2003; 115:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong BH, Brighton TA, Baker RI, et al. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005; 19:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramacciotti E, Araújo GR, Lastoria S, et al. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res 2004; 114:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2018; 1:CD003076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo-Santos J, Lozano F, Lorente MA, et al. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs. Am J Med 2015; 128:90.e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kline JA, Jimenez D, Courtney DM, et al. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. Acad Emerg Med 2016; 23:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatib R, Ross S, Kennedy SA, et al. Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. Blood Adv 2020; 4:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douketis JD. Treatment of deep vein thrombosis: what factors determine appropriate treatment? Can Fam Physician 2005; 51:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodger M, Bredeson C, Wells PS, et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998; 159:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999; 159:2298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bäckman K, Carlsson P, Kentson M, et al. Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment. Scand J Prim Health Care 2004; 22:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huse DM, Cummins G, Taylor DC, Russell MW. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. Am J Manag Care 2002; 8:S10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002; 122:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000; 160:2926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Belt AG, Bossuyt PM, Prins MH, et al. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group. Thromb Haemost 1998; 79:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lissovoy G, Yusen RD, Spiro TE, et al. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Arch Intern Med 2000; 160:3160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White RH, Brunson A, Romano PS, et al. Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism: A Population-Based Study. Circulation 2016; 133:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123:1788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mismetti P, Rivron-Guillot K, Quenet S, et al. A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest 2007; 131:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson W, Nicholson WJ, Tolerico P, et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 2010; 170:1827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dabbagh O, Nagam N, Chitima-Matsiga R, et al. Retrievable inferior vena cava filters are not getting retrieved: where is the gap? Thromb Res 2010; 126:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li X, Haddadin I, McLennan G, et al. Inferior vena cava filter - comprehensive overview of current indications, techniques, complications and retrieval rates. Vasa 2020; 49:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streiff MB. Vena caval filters: a comprehensive review. Blood 2000; 95:3669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters. Indications, safety, effectiveness. Arch Intern Med 1992; 152:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest 2002; 122:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63:1675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med 2014; 127:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 2015; 313:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajduk B, Tomkowski WZ, Malek G, Davidson BL. Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: a prospective, observational cohort study. Chest 2010; 137:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox MA, Kahn SR. Postthrombotic syndrome in relation to vena cava filter placement: a systematic review. J Vasc Interv Radiol 2008; 19:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmila MR, Osborne NH, Henke PK, et al. Prophylactic Inferior Vena Cava Filter Placement Does Not Result in a Survival Benefit for Trauma Patients. Ann Surg 2015; 262:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schellong SM, Schwarz T, Kropp J, et al. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb Haemost 1999; 82 Suppl 1:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000; 32:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost 2001; 85:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa 2001; 30:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldrich D, Hunt DP. When can the patient with deep venous thrombosis begin to ambulate? Phys Ther 2004; 84:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson CM, Overend TJ, Godwin J, et al. Ambulation after deep vein thrombosis: a systematic review. Physiother Can 2009; 61:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aissaoui N, Martins E, Mouly S, et al. A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both. Int J Cardiol 2009; 137:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: a systematic review. Thromb Res 2008; 122:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007; 146:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002; 16:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsberg JS, Hirsh J, Julian J, et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 2001; 161:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partsch H, Kaulich M, Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol 2004; 23:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg 2008; 47:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain A, Cifu AS. Prevention, Diagnosis, and Treatment of Postthrombotic Syndrome. JAMA 2016; 315:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ 2016; 353:i2691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appelen D, van Loo E, Prins MH, et al. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 2017; 9:CD004174.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1362 Version 127.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27428935" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24658395" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25880598" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13797091" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4130258" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Source of non-lethal pulmonary emboli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/146995" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20439576" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25948149" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19718469" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12814982" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Natural history of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20971331" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16543962" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical relevance of distal deep vein thrombosis. Review of literature data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11685050" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12618686" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Short-term natural history of isolated gastrocnemius and soleal vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17681715" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858700" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20630682" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20630686" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of isolated soleal and gastrocnemius vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20694281" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22209612" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A meta-analysis of anticoagulation for calf deep venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26660731" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24879813" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25010443" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28316124" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32271939" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of distal deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33840522" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35038763" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27471209" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34630698" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prediction of bleeding events using the VTE-BLEED risk score in patients with venous thromboembolism receiving anticoagulant therapy (Review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23590273" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081101" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594426" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594425" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10871969" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11029476" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : UK patients with deep-vein thrombosis can be safely treated as out-patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279651" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14959908" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effect of intravenous heparin administration on duration of hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11331057" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Outpatient treatment of deep venous thrombosis in diverse inner-city patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12967695" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16082604" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15878544" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342210" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29315455" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Home versus in-patient treatment for deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25242230" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26765080" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32040553" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15751565" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of deep vein thrombosis: what factors determine appropriate treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21128814" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Oral rivaroxaban for symptomatic venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23808982" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Oral apixaban for the treatment of acute venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23991658" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19966341" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9834718" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10547169" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15119520" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11822346" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12114345" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11041899" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9493572" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261856" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Management of venous thromboembolism: a systematic review for a practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10366368" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11074747" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27048765" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422387" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17218580" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696949" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20926119" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Retrievable inferior vena cava filters are not getting retrieved: where is the gap?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32660360" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Inferior vena cava filter - comprehensive overview of current indications, techniques, complications and retrieval rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845895" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Vena caval filters: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1417371" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Inferior vena cava filters. Indications, safety, effectiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12226040" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Medical literature and vena cava filters: so far so weak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24576432" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24280176" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vena cava filters in unstable elderly patients with acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919526" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19880907" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: a prospective, observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18589311" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Postthrombotic syndrome in relation to vena cava filter placement: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26366537" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Prophylactic Inferior Vena Cava Filter Placement Does Not Result in a Survival Benefit for Trauma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9459643" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009794" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574272" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10695503" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11054217" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11204585" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11582950" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14984299" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : When can the patient with deep venous thrombosis begin to ambulate?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20514175" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Ambulation after deep vein thrombosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18691773" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18078981" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Physical activity in patients with deep venous thrombosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261857" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15313740" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9074574" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12163001" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The post-thrombotic syndrome: current knowledge, controversies, and directions for future research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11570939" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Prevention and treatment of postphlebitic syndrome: results of a 3-part study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15765034" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18372153" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25246013" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24315521" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26954414" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prevention, Diagnosis, and Treatment of Postthrombotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27245485" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28950030" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Compression therapy for prevention of post-thrombotic syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
